Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Minocycline in the Treatment of Angelman Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01531582
Recruitment Status : Unknown
Verified May 2014 by Edwin Weeber, Ph.D., University of South Florida.
Recruitment status was:  Active, not recruiting
First Posted : February 13, 2012
Last Update Posted : May 12, 2014
Information provided by (Responsible Party):
Edwin Weeber, Ph.D., University of South Florida

Tracking Information
First Submitted Date  ICMJE February 5, 2012
First Posted Date  ICMJE February 13, 2012
Last Update Posted Date May 12, 2014
Study Start Date  ICMJE April 2012
Estimated Primary Completion Date December 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 8, 2012)
A change from baseline in the Bayley Scales of Infant and Toddler Development, 2nd edition (BSID-II)Score [ Time Frame: Baseline, 8 weeks & 16 weeks ]
The primary outcome measure consists of improvement in raw and standard scores on the Bayley Scales of Infant and Toddler Development when post Minocycline administration results are compared to baseline results.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 8, 2012)
  • Normalization of the EEG (electroencephalogram) signature [ Time Frame: Baseline, 8 and 16 weeks ]
    The secondary outcome measures consist of normalization of the EEG signature when comparing post MC administration results to baseline results. Angelman syndrome patients have a characteristic EEG signature and are prone to seizure. It stands to reason then, if the administration of MC decreases the number of seizures, a difference in the EEG signature should be observed as well.
  • A change from baseline in the Vineland Adaptive Behavior Scale, 4th edition (Vineland-II)Score [ Time Frame: Baseline, 8 and 16 weeks ]
    This test is to measure the adaptive behaviors; the ability to adapt to changes in one's environment, learn new everyday skills and level of independence.
  • A change from baseline in the Aberrant Behavior Checklist - Community version (ABC - Community)Score [ Time Frame: Baseline, 8 and 16 weeks ]
    This behavior rating scale utilizes direct observation to measure behavior problems in those with mental retardation. The checklist evaluates irritability, lethargy, stereotypic behavior, hyperactivity, inappropriate speech and provides a raw score for each domain.
  • A change from baseline in the Preschool Language Scale, Fourth Edition (PLS-4)Score [ Time Frame: Baseline, 8 and 16 weeks ]
    This test is used to evaluate the development of expressive and receptive language development. It also can be used to assess behaviors considered to be language precursors.
  • A change from baseline in the Clinical Global Impressions Severity Scale Score [ Time Frame: Baseline, 8 & 16 weeks ]
    The CGI is a brief assessment used by the clinician to describe the participants condition before and after the administration of a study medication.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Minocycline in the Treatment of Angelman Syndrome
Official Title  ICMJE The Efficacy of Minocycline in the Treatment of Angelman Syndrome
Brief Summary There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics. However, a recent surge of potential therapeutics for other disorders associated with cognitive disruption has begun to be used in human clinical trials. The molecular modes of action for many of these new therapeutic agents have correlates to counter the molecular defects observed in AS. One such agent is minocycline (MC), a drug traditionally used as an antibiotic. This compound administered to a mouse model of AS showed a significant decrease in motor deficit and an increase in long term potentiation. The investigators believe a similar result will be observed when minocycline is administered to the AS patient and may lead to the development of an effective AS therapeutic.
Detailed Description

This prospective single arm cohort study is to be conducted at the University of South Florida. The study will examine the effect minocycline (MC) has on the traits of Angelman Syndrome.

Minocycline HCl is an FDA approved antimicrobial medication in the tetracycline family of drugs. Of all the tetracyclines, MC is the most lipid soluble and most active. Unlike other antibiotics in this family, MC possesses the unique characteristic of being able to cross the blood brain barrier. The study dosage has been used in other trial treatments of other neurologic disorders with positive outcomes. Studies of long-term administration of MC at the study dose have been shown to be safe and well tolerated. This dosage has already been approved by the FDA for use in the treatment of bacterial infections of multiple organ systems, and acne vulgaris.

It is important to note that minocycline is not approved to treat Angelman syndrome or to be used in children younger than 8 years old. The study protocol has been reviewed by several physicians and scientists and been deemed safe to proceed. As with any medication the potential for side effects exist. The side effects range from serious to mild and include allergic reactions to upset stomach. In order to minimize this risk, the medical staff will perform a thorough medical history and physical examination before the prescription is issued to ensure no allergy to this medication, penicillin or another tetracycline exists. Discoloration of the teeth is potential adverse effect that exists when taking high doses of MC over long periods of time. The tooth discoloration is permanent and the parent or guardian of the participants will be made aware of this potential side effect prior to enrollment in the study. In other studies using MC, the most common complaint was gastrointestinal upset.

Recruitment & Prescreening - We anticipate some of the study participants will live far from the study site. In order to reduce screen failures (travel to the site only to find out your child doesn't meet the study criteria) the following process is required. To give parents the opportunity to consider the study and have time to consult with their doctor(s), we will begin recruitment approximately one week after the study has been published on this website. Parents will be asked to submit their information electronically by clicking the link at the bottom of this webpage or by accessing In the event they do not have internet access, they may call the study coordinator for assistance. Once you have indicated your interest in participation, a packet of information will be sent to you via email (or postal service if you prefer). The packet will include an informed consent document, a release of medical information and a form for your primary care doctor to complete and return directly to us. All of this information will be reviewed by the medical staff to determine your child's eligibility. Out of the first 50 eligible participants, 24 will be randomly selected by the Clinical and Investigational Science Institute (CTSI) at USF.

Study Procedure - Those selected will be required to travel to the study site a total of 3 times for 2 days each at their own expense (some assistance may be available through the Foundation for Angelman Syndrome Therapeutics, visit It is important that you seriously consider your ability to complete the study. The number of participants we are allowed to enroll is strictly governed and funding is limited. It is imperative data is collected from each of the 24 participants to ensure the best possible results. We do not know if your child will benefit from receiving this medication, which is why we are doing this study.

During the visits your child will be asked to provide a blood sample and undergo an electroencephalogram gram (EEG), physical examination as well as behavioral assessments. During the first visit, the study drug, minocycline, will be dispensed to you. You will be asked to administer the study drug to your child twice daily. You will also be asked to log the administration to confirm compliance with the study regimen. A telephone interview will be conducted with you after 4 weeks of treatment to assess drug tolerance and to record any changes you may have observed. The study medication will be discontinued after 8 weeks of treatment. At the same time point, you will have to return to the study site for a follow up visit identical to the primary visit. The final follow up visit will occur at the 16 week time point (8 weeks following the minocycline treatment). This visit will be identical to the first two visits and will assess the lasting effects of the medication. Below is a summary of the study procedures.

Summary of Study Procedures:

  1. Recruitment Begins - Interested parents contact the study staff via the internet form.
  2. Prescreening packets are sent - Informed Consent Document, Health Information Release & Primary Care Physician (PCP) questionnaire
  3. Eligibility Determined for 30 potential participants
  4. Random Selection of 24 participants
  5. Baseline Testing - Informed Consent Obtained, Lab work and EEG performed History and Physical exam performed
  6. Enrollment - Study Neurologist confirms the participant meets the study criteria.
  7. Behavioral Assessment
  8. Minocycline Administration
  9. Telephone Interview (4 weeks)
  10. Discontinue Minocycline (8 weeks)
  11. Follow up Assessment (8 weeks)
  12. Telephone Interview (12 weeks)
  13. Final Follow up assessment (16 weeks)

At the bottom of the page you will find a link to the website. There you will be able to submit your contact information.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Angelman Syndrome
Intervention  ICMJE Drug: minocycline
The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
Other Names:
  • Alti-Minocycline
  • Apo-Minocycline
  • Arestin
  • Dynacin
  • Gen-Minocycline
  • Klinomycin
  • Minociclina [INN-Spanish]
  • Minocin
  • Minocyclin
  • Minocycline HCl
  • Minocyclinum [INN-Latin]
  • Minocyn
  • Minomycin
  • Novo-Minocycline
  • Solodyn
  • Vectrin
  • Tetracycline
Study Arms  ICMJE Experimental: Children with Angelman Syndrome
Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
Intervention: Drug: minocycline
Publications * Grieco JC, Ciarlone SL, Gieron-Korthals M, Schoenberg MR, Smith AG, Philpot RM, Heussler HS, Banko JL, Weeber EJ. An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. BMC Neurol. 2014 Dec 10;14:232. doi: 10.1186/s12883-014-0232-x.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Unknown status
Actual Enrollment  ICMJE
 (submitted: June 27, 2013)
Original Estimated Enrollment  ICMJE
 (submitted: February 8, 2012)
Estimated Study Completion Date  ICMJE December 2014
Estimated Primary Completion Date December 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. The participant is between the ages of 4 to 12 years old.
  2. The participant has been previously diagnosed with AS by clinical evaluation.
  3. The participant's diagnosis has molecular confirmation (e.g. karyotyping, fluorescent in situ hybridization (FISH), DNA methylation test or sequencing of the ubiquitin-protein ligase E3A gene) of the diagnosis.
  4. The participant has a CGI-Severity Score of at least 4 indicating a moderate level of behavioral difficulty.
  5. The participant is male or female.
  6. The participant has an acceptable surrogate capable of giving consent on the participant's behalf.

Exclusion Criteria:

  1. The participant was diagnosed with AS with no identifiable molecular abnormality.
  2. The participant has a known allergy to MC or tetracycline.
  3. The participant is currently enrolled in a study in which a drug, vitamin or dietary manipulation is used in the treatment of AS.
  4. The participant suffers from severe or uncontrolled seizures or any other medical condition rendering the patient unstable.
  5. The participant suffers from cardiovascular, respiratory, liver, kidney or hematologic disease.
  6. The participant suffers from liver disease or elevated liver function tests.
  7. The participant has a history of neutropenia, anemia or thrombocytopenia.
  8. The participant has a history of systemic lupus erythematosus or an anti-nuclear antibody (ANA) titer or >1:40.
  9. The participant is pregnant or at risk of becoming pregnant (sexually active females).
  10. The participant experiences persistent psychotic symptoms.
  11. The participant (or a parent/caregiver) is not willing to participate in clinic visits.
  12. The participant experiences severe symptoms judged to likely to endanger the participant's safety or the safety of others.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 4 Years to 12 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01531582
Other Study ID Numbers  ICMJE WEEBER001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Edwin Weeber, Ph.D., University of South Florida
Study Sponsor  ICMJE University of South Florida
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Edwin J Weeber, Ph.D. University of South Florida
PRS Account University of South Florida
Verification Date May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP